Reply to Mahe, Rousseau, Saumet, and Abraham

Abstract

LETTERS TO THE EDITORReply to Mahe, Rousseau, Saumet, and AbrahamLacy A. Holowatz and W. Larry KenneyLacy A. Holowatz and W. Larry KenneyPublished Online:01 Apr 2009https://doi.org/10.1152/japplphysiol.00038.2009MoreSectionsPDF (30 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations to the editor: We thank Dr. Mahe and colleagues (2) for their letter commenting on our recent findings that chronic low-dose aspirin therapy (81 mg) consistently and significantly attenuates reflex-mediated cutaneous vasodilation during heat stress (1). Daily low-dose aspirin (81 mg) is the gold standard antiplatelet therapy for primary and secondary prevention of atherothrombotic disease. Furthermore, the number of individuals engaging in medically supervised and unsupervised aspirin therapy is increasing because of the proven and substantiated cardiovascular benefits (3).Our recent findings provide the initial observation that reflex vasodilation in aged humans engaging in aspirin therapy is attenuated. However, before we make recommendations for altering antiplatelet drug therapy during environmental heat exposure, additional research is needed to determine 1) whether low-dose aspirin is effecting central thermoregulatory control, in which case sweating responses may also be diminished, 2) whether other antiplatelet drugs have similar effects on reflex vasodilation, and 3) whether lower doses (<81 mg) of aspirin provide sufficient antiplatelet effects without impairing reflex cutaneous vasodilation. This research into these basic mechanisms is necessary to provide evidenced-based recommendations and potential interventions for vulnerable clinical populations during heat exposure.REFERENCES1 Holowatz LA, Kenney WL. Chronic low-dose aspirin therapy attenuates reflex cutaneous vasodilation in middle-aged humans. J Appl Physiol 106: 500–505, 2009.Link | ISI | Google Scholar2 Mahe G, Rousseau P, Saumet JL, Abraham. About “Chronic low-dose aspirin therapy attenuates reflex cutaneous vasodilatation in middle-aged humans.” J Appl Physiol; doi:10.1152/japplphysiol.91653.2008.Link | ISI | Google Scholar3 Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol 28: s25–32, 2008.Crossref | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: L. A. Holowatz, 204 Noll Lab, Penn State, Univ. Park, PA 16802 (e-mail: [email protected]) Download PDF Previous Back to Top Next FiguresReferencesRelatedInformation More from this issue > Volume 106Issue 4April 2009Pages 1472-1472 Copyright & PermissionsCopyright © 2009 the American Physiological Societyhttps://doi.org/10.1152/japplphysiol.00038.2009History Published online 1 April 2009 Published in print 1 April 2009 Metrics